drugset / Trial / NCT00442104

Open-label Extension to Protocol 1042-0500

NCT00442104

Phase 2 Terminated 54 enrolled Marinus Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

To allow open-label extension to patients who have completed Protocol 1042-0500

Timeline

Start
2007-01
Primary completion
2009-03
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Ganaxolone Small molecule

Indications